Qiagen Acquires Point-of-Care Test Maker AmniSure | GenomeWeb

NEW YORK (GenomeWeb News) – Qiagen said after the close of the market Thursday that it has acquired AmniSure International, a privately held point-of-care diagnostics firm, for an undisclosed amount.

Boston-based AmniSure sells an assay for determining whether a pregnant woman is suffering rupture of fetal membranes. Qiagen said as many as 30 percent of pregnant women are checked for this condition in clinical settings.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.